Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
Open accessThe DOI matches its Crossref record; 287 of the 288 references it cites were found in a registry or an index.
Abstract
Since its clinical introduction in 1998, the topoisomerase I inhibitor irinotecan has been widely used in the treatment of solid tumors, including colorectal, pancreatic, and lung cancer. Irinotecan therapy is characterized by several dose-limiting toxicities and large interindividual pharmacokinetic variability. Irinotecan has a highly complex metabolism, including hydrolyzation by carboxylesterases to its active metabolite SN-38, which is 100- to 1000-fold more active compared with irinotecan itself. Several phase I and II enzymes, including cytochrome P450 (CYP) 3A4 and uridine diphosphate glucuronosyltransferase (UGT) 1A, are involved in the formation of inactive metabolites, making its metabolism prone to environmental and genetic influences. Genetic variants in the DNA of these enzymes and transporters could predict a part of the drug-related toxicity and efficacy of treatment, which has been shown in retrospective and prospective trials and meta-analyses. Patient characteristics, lifestyle and comedication also influence irinotecan pharmacokinetics. Other factors, including dietary restriction, are currently being studied. Meanwhile, a more tailored approach to prevent excessive toxicity and optimize efficacy is warranted. This review provides an updated overview on today's literature on irinotecan pharmacokinetics, pharmacodynamics, and pharmacogenetics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Irinotecan or its activated form SN38 can be metabolically inactivated by uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1), cytochrome P450-3A4 (CYP3A4) and β-glucuronidase [104].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–287 of 287
Selective Serotonin Reuptake Inhibitor-induced Rhabdomyolysis Associated with Irinotecan
Richards, S., Umbreit, J. N., Fanucchi, M. P., Giblin, J., & Khuri, F. R. (2003) · Southern Medical Journal · doi:10.1097/01.smj.0000084311.35864.d6 · Cited by 42 · cited 1×
“Anecdotally, severe rhabdomyolysis syndrome has been described in a patient using irinotecan and citalopram [143].”
BackgroundInoue, K., Sonobe, M., Kawamura, Y., Etoh, T., Takagi, M., Matsumura, T., Kikuyama, M., Kimura, M., Minami, S., Utsuki, H., et al. (2013) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.229.107 · Cited by 41
Irinotecan Loaded in Eluting Beads: Preclinical Assessment in a Rabbit VX2 Liver Tumor Model
Rao, P. P., Pascale, F., Seck, A., Auperin, A., Drouard-Troalen, L., Deschamps, F., Teriitheau, C., Paci, A., Denys, A. L., Bize, P., et al. (2012) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-012-0343-y · Cited by 41
Huisman, S. A., de Bruijn, P., Moghaddam-Helmantel, I. M. G., IJzermans, J. N. M., Wiemer, E. A. C., Mathijssen, R. H. J., & de Bruin, R. W. F. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13317 · Cited by 41 · cited 1×
“Systemic and hepatic exposure to SN-38 was reduced in these mice, but intratumoral concentrations were unaltered [202, 203].”
BackgroundSelf-citationLoos, W. J., Verweij, J., Gelderblom, H. A. J., Jonge, M. J. D., Brouwer, E., Dallaire, B. K., & Sparreboom, A. (1999) · Anti-Cancer Drugs · doi:10.1097/00001813-199909000-00003 · Cited by 39 · cited 1×
“Alternatively, release of SN-38 from erythrocytes has also been proposed to cause this second plasma peak [17].”
BackgroundPhase I and Pharmacokinetic Study of Docetaxel and Irinotecan in Patients With Advanced Solid Tumors
Couteau, C., Risse, M., Ducreux, M. P., Lefresne-Soulas, F., Riva, A., Lebecq, A., Ruffiè, P., Rougier, P. R., Lokiec, F. M., Bruno, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.20.3545 · Cited by 39
Dias, M. M., Pignon, J., Karapetis, C. S., Boige, V., Glimelius, B. L. G., Kweekel, D. M., Lara, P. N., Laurent‐Puig, P., Martinez‐Balibrea, E., Páez, D., et al. (2014) · The Pharmacogenomics Journal · doi:10.1038/tpj.2014.16 · Cited by 39 · cited 7×
“Two clinical studies did not report any significant associations between UGT1A1*60 status and Table 3 Overview of pharmacogenetic studies on irinotecan toxicity and survival Polymorphism Ethnicity Endpoint Dose range (mg/m2) Main findings No. of patients No. of studies References Meta-analyses UGT1A1*28/*28 (rs8175347…”
BackgroundInfluentialCost Evaluation of Irinotecan‐Related Toxicities Associated With the UGT1A1*28 Patient Genotype
Roncato, R., Cecchin, E., Montico, M., Mattia, E. D., Giodini, L., Buonadonna, A., Solfrini, V., Innocenti, F., & Toffoli, G. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.615 · Cited by 38 · cited 1×
“This is also accompanied by increased financial costs of toxicity management [241].”
BackgroundKudoh, S., Fukuoka, M., Masuda, N., Yoshikawa, A., Kusunoki, Y., Matsui, K., Negoro, S., Takifuji, N., Nakagawa, K., Hirashima, T., et al. (1995) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1995.tb03071.x · Cited by 38
Yi, B.-R., Kim, S. U., & Choi, K.-C. (2014) · Oncotarget · doi:10.18632/oncotarget.2547 · Cited by 37
Phase II Trial of Upfront Bevacizumab, Irinotecan, and Temozolomide for Unresectable Glioblastoma
Peters, K. B., Lou, E., Desjardins, A., Reardon, D. A., Lipp, E., Miller, E. A., Herndon, J. E., McSherry, F., Friedman, H. S., & Vredenburgh, J. J. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0135 · Cited by 37
Rtibi, K., Selmi, S., Grami, D., Sebaï, H., Amri, M., & Marzouki, L. (2017) · Pathophysiology · doi:10.1016/j.pathophys.2017.07.002 · Cited by 37
de Jonge, M. J. A., Sparreboom, A., Planting, A. S. T., van der Burg, M. E. L., de Boer-Dennert, M. M., ter Steeg, J., Jacques, C. J., & Verweij, J. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.1.187 · Cited by 36
Jang, H. J., Kim, B. J., Kim, J. H., & Kim, H. S. (2017) · Oncotarget · doi:10.18632/oncotarget.20314 · Cited by 35
Pan, C.-X., Loehrer, P., Seitz, D., Helft, P., Juliar, B., Ansari, R., Pletcher, W., Vinson, J., Cheng, L., & Sweeney, C. (2005) · Oncology · doi:10.1159/000087302 · Cited by 34
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors
Denlinger, C. S., Blanchard, R. L., Xu, L., Bernaards, C. A., Litwin, S., Spittle, C. S., Berg, D., McLaughlin, S. B., Redlinger, M., Dorr, A., et al. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1008-7 · Cited by 33
Younis, I. R., Malone, S., Friedman, H. S., Schaaf, L. J., & Petros, W. P. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0769-8 · Cited by 33 · cited 1×
“SN-38 is reabsorbed after intestinal deconjugation of SN-38G by (bacterial) b-glucuronidases [15].”
BackgroundGlockzin, G., Gerken, M., Lang, S. A., Klinkhammer‐Schalke, M., Piso, P., & Schlitt, H. J. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-807 · Cited by 33
Ferraldeschi, R., Minchell, L. J., Roberts, S. A., Tobi, S., Hadfield, K. D., Blackhall, F. H., Mullamitha, S., Wilson, G., Valle, J. W., Saunders, M. P., et al. (2009) · Pharmacogenomics · doi:10.2217/pgs.09.20 · Cited by 32
Lévi, F., Karaboué, A., Étienne-Grimaldi, M.-C., Paintaud, G., Focan, C., Innominato, P. F., Bouchahda, M., Milano, G. A., & Chatelut, É. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0431-2 · Cited by 32 · cited 1×
“First, locoregional therapy with irinotecan infusion into the hepatic artery has been evaluated for the treatment of unresectable liver metastases; different irinotecan formulations have been demonstrated to be safe and effective [95, 96].”
BackgroundPhase II study of irinotecan in combination with bevacizumab in recurrent ovarian cancer
Musa, F., Pothuri, B., Blank, S. V., Ling, H. T., Speyer, J. L., Curtin, J. P., Boyd, L. R., Li, X., Goldberg, J. D., Muggia, F. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.11.043 · Cited by 32
Chen, X., Liu, L., Guo, Z., Liang, W., He, J., Huang, L., Deng, Q., Tang, H., Pan, H., Guo, M., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3306-9 · Cited by 32 · cited 4×
“Several meta-analyses in Asian patients with different tumor types and treatment schedules did not show any significant association between UGT1A1*28 and irinotecan-induced neutropenia [245, 246].”
BackgroundInfluentialGarufi, C., Vanni, B., Aschelter, A. M., Zappalà, A. R., Bria, E., Nisticò, C., Sperduti, I., Cognetti, F., & Terzoli, E. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.03.012 · Cited by 31
Tallman, M. N., Ritter, J. K., & Smith, P. C. (2005) · Drug Metabolism and Disposition · doi:10.1124/dmd.104.003491 · Cited by 30
Meck, M. M., Wierdl, M., Wagner, L. M., Burger, R. A., Guichard, S. M., Krull, E. J., Harris, L. C., Potter, P. M., & Danks, M. K. (2001) · PubMed · Cited by 29
Soepenberg, O., Dumez, H., Verweij, J., Sémiond, D., deJonge, M. J. A., Eskens, F. A. L. M., ter Steeg, J., Selleslach, J., Assadourian, S., Sanderink, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.008 · Cited by 29
Cotte, E., Passot, G., Tod, M. M., Bakrin, N., Gilly, F., Steghens, A., Mohamed, F., & Gléhen, O. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1651-1 · Cited by 29
Gutova, M., Najbauer, J., Y. Chen, M., M. Potter, P., U. Kim, S., & S. Aboody, K. (2010) · Current Stem Cell Research & Therapy · doi:10.2174/157488810791824421 · Cited by 28
Meyerhardt, J. A., Clark, J. W., Supko, J. G., Eder, J. P., Ogino, S., Stewart, C. F., D’Amato, F., Dancey, J. E., Enzinger, P. C., Zhu, A. X., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0411-6 · Cited by 28
Kim, S. Y., Hong, Y. S., Shim, E., Kong, S.-Y., Shin, A., Baek, J. Y., & Jung, K. H. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.479 · Cited by 28
Crona, D. J., Ramírez, J., Qiao, W., de Graan, A.-J. M., Ratain, M. J., van Schaik, R. H. N., Mathijssen, R. H. J., Rosner, G. L., & Innocenti, F. (2015) · The Pharmacogenomics Journal · doi:10.1038/tpj.2015.23 · Cited by 28
Self-citationYchou, M., Douillard, J.-Y., Rougier, P. R., Adenis, A., Mousseau, M., Dufour, P., Wendling, J. L., Bürki, F., Mignard, D., & Marty, M. E. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200004000-00008 · Cited by 27 · cited 1×
“use of racecadotril, an antisecretory drug, also failed to reduce this adverse event [190].”
BackgroundPitot, H. C., Adjei, A. A., Reid, J. M., Sloan, J. A., Atherton, P. J., Rubin, J., Alberts, S. R., Duncan, B. A., Denis, L., Schaaf, L. J., et al. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-0138-9 · Cited by 27
Bennouna, J., Deslandres, M., Senellart, H., de Labareyre, C., Ruiz-Soto, R., Wixon, C., Botbyl, J., Suttle, A. B., & Delord, J.-P. (2015) · Investigational New Drugs · doi:10.1007/s10637-014-0142-1 · Cited by 26
Oosterhoff, D., Overmeer, R. M., de Graaf, M., van der Meulen, I. H., Giaccone, G., van Beusechem, V. W., Haisma, H. J., Pinedo, H. M., & Gerritsen, W. R. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602362 · Cited by 26
Ford, H. E. R., Cunningham, D., Ross, P. J., Rao, S., Aherne, G. W., Benepal, T., Price, T. J., Massey, A., & Vernillet, L. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1192 · Cited by 26
Delord, J., Pierga, J., Dieras, V. C., Bertheault-Cvitkovic, F., Turpin, F., Lokiec, F. M., Lochon, I., Chatelut, É., Canal, P., Guimbaud, R., et al. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602354 · Cited by 26
Berg, A. K., Buckner, J. C., Galanis, E., Jaeckle, K. A., Ames, M. M., & Reid, J. M. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.543 · Cited by 26 · cited 6×
“Concomitant treatment with non-anticancer drugs such as AEDs, certain antidepressants, antiretroviral drugs, and nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to affect irinotecan pharmacokinetics or pharma- codynamics.”
BackgroundInfluentialMiddleton, G., Brown, S., Lowe, C., Maughan, T., Gwyther, S. J., Oliver, A., Richman, S. D., Blake, D. R., Napp, V., Marshall, H. C., et al. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.06.017 · Cited by 25
Yumuk, P. F., Aydin, S. Z., Dane, F., Gümüş, M., Ekenel, M., Aliustaoğlu, M., Karamanoğlu, A. Y., Şengöz, M., & Turhal, S. N. (2004) · International Journal of Colorectal Disease · doi:10.1007/s00384-004-0613-5 · Cited by 25 · cited 1×
“atropine or hyoscyamine) before irinotecan infusion [176, 177].”
Herb–Drug Interactions in Oncology
Goey, A. K. L., Beijnen, J. H., & Schellens, J. H. M. (2014) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2014.18 · Cited by 25 · cited 1×
“Unfortunately, the potential for herb–drug interactions in oncology is not frequently investigated in clinical studies [157].”
BackgroundSelf-citationGiacchetti, S., Curé, H., Adenis, A., Tubiana-Mathieu, N., Vernillet, L., Chedouba-Messali, L., Chevalier, V., Germa, C., Chollet, P. J. M., & Lévi, F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)81635-x · Cited by 25 · cited 1×
“However, pharmacokinetic consequences have only been investigated in a small randomized study in which an increased metabolic ratio (SN-38/irinotecan AUC) and smaller interindividual variability were found after circadian-timed dosing [94].”
BackgroundChen, Y.-J., Hu, F., Li, C., Fang, J., Chu, L., Zhang, X., & Xu, Q. (2013) · Biomarkers · doi:10.3109/1354750x.2013.867534 · Cited by 24
Altered irinotecan metabolism in a patient receiving phenytoin
Mathijssen, R. H. J., Sparreboom, A., Dumez, H., van Oosterom, A. T., & de Bruijn, E. A. (2002) · Anti-Cancer Drugs · doi:10.1097/00001813-200202000-00004 · Cited by 23 · cited 2×
“…[188] 48 125–150 mg/m2 Q1W No No ND ND Herben et al., 1999 [184] 29 10–12.5 mg/m2 D14–21, continuously No No No No de Jong et al., 2000 [66] 52 175–300 mg/m2 Q3W No No ND ND Mathijssen et al., 2002 [73] 26 350 mg/m2 Q3W ND Yesf ND ND All assumed relationships mentioned are significant at p\0.05 N…”
BackgroundInfluentialSelf-citationMurren, J. R., Peccerillo, K., DiStasio, S. A., Li, X., Leffert, J. J., Pizzorno, G., Burtness, B. A., McKeon, A. M., & Cheng, Y. C. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000115 · Cited by 23 · cited 1×
“Sequencing the administration of paclitaxel after irinotecan seems to improve their synergistic anticancer effects [125], but irinotecan pharmacokinetics are not significantly altered in”
BackgroundInternational, O. B. O. A., Lévi, F., Karaboué, A., Saffroy, R., Desterke, C., Boige, V., Smith, D. M., Hebbar, M., Innominato, P. F., Taïeb, J., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.278 · Cited by 23
Argiris, A. E., Kut, V., Luong, L. N. L., & Avram, M. J. (2005) · Investigational New Drugs · doi:10.1007/s10637-005-3259-4 · Cited by 22
van der Bol, J. M., Loos, W. J., de Jong, F. A., van Meerten, E., Konings, I. R. H. M., Lam, M. H., de Bruijn, P., Wiemer, E. A. C., Verweij, J., & Mathijssen, R. H. J. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.11.030 · Cited by 22 · cited 1×
“Although omeprazole influences UGT, CYP3A, ABCB1, and ABCG2, a clinically relevant pharmacokinetic interaction with irinotecan was ruled out in a small crossover study [154].”
BackgroundSelf-citationYang, X., Li, C., Xu, M., Zhao, H., & Wang, D. (2015) · BMC Cancer · doi:10.1186/s12885-015-1978-2 · Cited by 22 · cited 1×
“For advanced NSCLC, irinotecan combined with taxanes, platinum, ifosfamide, or gemcitabine demonstrated efficacy as firstline treatment in several trials [222].”
BackgroundUchino, J., Takayama, K., Harada, A., Sone, T., Harada, T., Curiel, D. T., Kuroki, M., & Nakanishi, Y. (2008) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701100 · Cited by 21
Ettlinger, D. E., Mitterhauser, M., Wadsak, W., Ostermann, E., Farkouh, A., Schueller, J., & Czejka, M. J. (2006) · PubMed · Cited by 21
Choi, M. K., Ahn, B.-J., Yim, D., Park, Y. S., Kim, S., Sohn, T. S., Noh, J. H., Heo, J. S., Lee, J., Park, S. H., et al. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1272-6 · Cited by 21
Kee, B. K., Morris, J. S., Slack, R. S., Crocenzi, T. S., Wong, L., Esparaz, B., Overman, M. J., Glover, K. Y., Jones, D., Wen, S., et al. (2014) · Supportive Care in Cancer · doi:10.1007/s00520-014-2402-1 · Cited by 20 · cited 1×
“Until now, only the activated charcoal has been found to reduce the incidence of diarrhea [191, 192]; however, evidence from a phase III study and additional pharmacokinetic analysis is warranted to understand the real effect of activated charcoal, which also exhibits a general antidiarrhoeic effect, and therefore the…”
BackgroundGilbert, J., Cmelak, A. J., Shyr, Y., Netterville, J. L., Burkey, B. B., Sinard, R. J., Yarbrough, W., Chung, C. H., Aulino, J. M., & Murphy, B. A. (2008) · Cancer · doi:10.1002/cncr.23545 · Cited by 19
Poujol, S., Pinguet, F., Ychou, M., Abderrahim, A. G., Duffour, J., & Bressolle, F. (2007) · Oncology Reports · doi:10.3892/or.18.6.1613 · Cited by 19
Roy, A. C., Cunningham, D., Hawkins, R. E., Sørbye, H., Adenis, A., Barcelo, J.-R., López-Vivanco, G., Adler, G., Canon, J.-L., Lofts, F. J., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.286 · Cited by 19
Boven, E., Massard, C., Armand, J., Tillier, C., Hartog, V., Brega, N. M., Countouriotis, A., Ruiz-García, A., & Soria, J. (2010) · British Journal of Cancer · doi:10.1038/sj.bjc.6605852 · Cited by 19
Ahn, B.-J., Choi, M. K., Park, Y. S., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., Ko, J.-W., & Yim, D. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0885-3 · Cited by 18 · cited 1×
“A small fraction of irinotecan is rapidly converted intraperitoneally into SN38; systemic maximum concentration (Cmax) of SN-38 has been observed 30 min after intraperitoneal administration [98, 100].”
BackgroundInfluence of various bile salts on ββ‐glucuronidase activity of intestinal bacteria
Fujisawa, T., & Mori, M. (1997) · Letters in Applied Microbiology · doi:10.1046/j.1472-765x.1997.00180.x · Cited by 18
Brell, J. M., Krishnamurthi, S., Javle, M. M., Saltzman, J. N., WOLLNER, I. S., Pelley, R. J., Dowlati, A., Kantharaj, B. N., SCHLUCHTER, M. D., Rath, L., et al. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0807-6 · Cited by 17
Hofheinz, R., Kubicka, S., Wollert, J., Arnold, D., & Hochhaus, A. (2006) · Oncology Research and Treatment · doi:10.1159/000096449 · Cited by 17
Lustberg, M. B., Bekaii‐Saab, T., Young, D., Otterson, G. A., Burak, W. E., Abbas, A., McCracken-Bussa, B., Lustberg, M. E., & Villalona-Calero, M. A. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d7776d · Cited by 16
Effect of Cellular Location of Human Carboxylesterase 2 on CPT-11 Hydrolysis and Anticancer Activity
Hsieh, Y.-T., Lin, H.-P., Chen, B., Huang, P.-T., & Roffler, S. R. (2015) · PLoS ONE · doi:10.1371/journal.pone.0141088 · Cited by 16
Cheng, C., Lau, J., & Earl, M. A. (2015) · The Journal of Community and Supportive Oncology · doi:10.12788/jcso.0099 · Cited by 16 · cited 1×
“atropine or hyoscyamine) before irinotecan infusion [176, 177].”
Choi, S. S., Yoon, K., Choi, S.-A., Yoon, S.-B., Kim, S. U., & Lee, H. J. (2016) · Oncotarget · doi:10.18632/oncotarget.12173 · Cited by 15
Delioukina, M. L., Prager, D., Parson, M., Hecht, J. R., Rosen, P. J., & Rosen, L. S. (2002) · Cancer · doi:10.1002/cncr.10432 · Cited by 15
Oral irinotecan for treatment of pediatric solid tumors: Ready for prime time?
Wagner, L. M. (2010) · Pediatric Blood & Cancer · doi:10.1002/pbc.22410 · Cited by 14 · cited 1×
“First, oral administration of several different formulations has been investigated and deemed feasible in phase I trials [79–81], but its poor and highly variable bioavailability have limited its current clinical usability [82].”
BackgroundCzejka, M. J., Schueller, J., Hauer, K., & Ostermann, E. (2005) · PubMed · Cited by 13
Moreno, V. V., Brunet, J., Alemany, H. M., Salvia, A. S., Serentill, M. L., Montero, I. C., Servitja, S., Bert, E. S., & Padró, J. G. (2006) · Clinical & Translational Oncology · doi:10.1007/s12094-006-0012-1 · Cited by 12
Allegrini, G., Paolo, A. D., Cerri, E., Cupini, S., Amatori, F., Masi, G., Danesi, R., Marcucci, L., Bocci, G., Tacca, M. D., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0205-x · Cited by 12 · cited 2×
“Patients seemed to tolerate irinotecan better when thalidomide was coadministered in two phase II studies in which SN-38G exposure was increased at the expense of SN-38 exposure [130].”
BackgroundPhase I study of oral irinotecan as a single-agent and given sequentially with capecitabine
Goff, L. W., Benson, A. B., LoRusso, P. M., Tan, A. R., Berlin, J. D., Denis, L., Benner, R. J., Yin, D., & Rothenberg, M. L. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9528-x · Cited by 11
Thalidomide and celecoxib as potential modulators of irinotecan’s activity in cancer patients
Villalona-Calero, M. A., Schaaf, L. J., Phillips, G. S., Otterson, G. A., Panico, K., Duan, W., Kleiber, B., Shah, M. H., Young, D. C., Wu, W.-H., et al. (2006) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-006-0249-y · Cited by 10 · cited 2×
“However, the pharmacokinetic differences could not be replicated [131, 132] and might be caused by confounding as half of the patients also used antiepileptic drugs (AEDs) [130].”
BackgroundYokoo, K., Hamada, A., Watanabe, H., Matsuzaki, T., Imai, T., Fujimoto, H., Masa, K., Imai, T., & Saito, H. (2007) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.015164 · Cited by 10
Horita, Y., Yamada, Y., Hirashima, Y., Kato, K., Nakajima, T. E., Hamaguchi, T., & Shimada, Y. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1051-4 · Cited by 10
Goel, S., Desai, K. K., Karri, S., Gollamudi, R., Chaudhary, I., Bulgaru, A., Kaubisch, A., Goldberg, G. L., Einstein, M. H., Camacho, F., et al. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9028-1 · Cited by 10
Said, R., Kurzrock, R., Naing, A., Hong, D. S., Fu, S., Piha-Paul, S. A., Wheler, J. J., Jankú, F., Kee, B. K., Bidyasar, S., et al. (2015) · Investigational New Drugs · doi:10.1007/s10637-015-0251-5 · Cited by 10 · cited 1×
“First, locoregional therapy with irinotecan infusion into the hepatic artery has been evaluated for the treatment of unresectable liver metastases; different irinotecan formulations have been demonstrated to be safe and effective [95, 96].”
BackgroundEffects of methimazole on the elimination of irinotecan
van der Bol, J. M., Visser, T. J., Loos, W. J., de Jong, F. A., Wiemer, E. A. C., van Aken, M. O., Planting, A. S., Schellens, J. H., Verweij, J., & Mathijssen, R. H. J. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1414-x · Cited by 9 · cited 1×
“In contrast, by UGT1A induction by methimazole, an increase in SN-38 and SN-38G concentrations, as well as an almost 50% increased ratio of SN38G/SN-38, was found by within-patient comparison (Table 1) [150].”
ResultSelf-citationHotta, K., Ueoka, H., Kiura, K., Tabata, M., Kuyama, S., Satoh, K., Kozuki, T., Hisamoto, A., Hosokawa, S., Fujiwara, K., et al. (2004) · Lung Cancer · doi:10.1016/j.lungcan.2004.01.001 · Cited by 9
Xu, Y., Kolesar, J., Schaaf, L. J., Drengler, R. L., Duan, W., Otterson, G. A., Shapiro, C. L., Kuhn, J. G., & Villalona-Calero, M. A. (2008) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-008-0826-3 · Cited by 9 · cited 1×
“Studies that did not show a significant drug–drug interaction [131, 132, 152, 153] are illustrated in more detail in the text 1234 F.”
BackgroundGarcía, A. A., Pujari, M. P., Jeffers, S., Iqbal, S., Lenz, H., Beringer, P. M., & Louie, S. G. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0940-9 · Cited by 6
Asai, G., Yamamoto, N., Kurata, T., Tamura, K., Uejima, H., Nakagawa, K., & Fukuoka, M. (2006) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(15)31572-0 · Cited by 6 · cited 1×
“In contrast, paclitaxel combined with irinotecan in a 3-weekly regimen caused a significant increase in irinotecan, SN-38, and SN38G exposure, which was assumed to be caused by competitive inhibition of ABCB1 (Table 1) [124].”
BackgroundRamírez, J., Wu, K., Janisch, L. A., Karrison, T., House, L. K., Innocenti, F., Cohen, E. E. W., & Ratain, M. J. (2011) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-011-1727-4 · Cited by 6 · cited 2×
“However, the pharmacokinetic differences could not be replicated [131, 132] and might be caused by confounding as half of the patients also used antiepileptic drugs (AEDs) [130].”
BackgroundYokoo, K., Hamada, A., Tazoe, K., Sasaki, Y., & Saito, H. (2009) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e31819c67e5 · Cited by 5
Bian, X., Liu, B., & Yang, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4299 · Cited by 4
Wang, D., Braiteh, F., Lee, J. J., Denlinger, C. S., Shepard, D. R., Chaudhary, A., Lin, Y., Gao, L., Asakiewicz, C., Nasroulah, F., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3125-4 · Cited by 3
Kee, B. K., Slack, R. S., Crocenzi, T. S., Wong, L., Esparaz, B. T., Overman, M. J., Glover, K. Y., Morris, J. S., & Fisch, M. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3600 · Cited by 1
Research works printed but not linked: 2
- National Institutes of Health Common terminology criteria for adverse events (CTCAE) 2010 Bethesda National Institutes of Health
- Murphy BA Cmelak A Burkey B Netterville J Shyr Y Douglas S Topoisomerase I inhibitors in the treatment of head and neck cancer Oncology (Williston Park) 2001 15 7 Suppl 8 47 52 11497232
Cited by
Anand, U., Dey, A., Chandel, A. K. S., Sanyal, R., Mishra, A., Pandey, D. K., De Falco, V., Upadhyay, A., Kandimalla, R., Chaudhary, A., et al. (2023) · Genes & Diseases · doi:10.1016/j.gendis.2022.02.007 · Cited by 1,834
Drug resistance and new therapies in colorectal cancer
Jeught, K. V. D., Xu, H.-C., Li, Y.-J., Lu, X.-B., & Ji, G. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i34.3834 · Cited by 597
Wainberg, Z. A., Melisi, D., Macarulla, T., Pazo Cid, R., Chandana, S. R., De La Fouchardière, C., Dean, A., Kiss, I., Lee, W. J., Goetze, T. O., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01366-1 · Cited by 516
Irinotecan: 25 years of cancer treatment
Bailly, C. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104398 · Cited by 456
Hwang, W. L., Jagadeesh, K. A., Guo, J. A., Hoffman, H. I., Yadollahpour, P., Reeves, J. W., Mohan, R., Drokhlyansky, E., Van Wittenberghe, N., Ashenberg, O., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01134-8 · Cited by 426
Metadata
- Authors
- de Man, F. M., Goey, A. K. L., van Schaik, R. H. N., Mathijssen, R. H. J., & Bins, S.
- Affiliations
- Erasmus MC (NL)
- Erasmus MC Cancer Institute (NL)
- Corresponding author
- Bins, Sander
- Venue
- Clinical Pharmacokinetics
- Published
- 2018-03-08
- Volume
- 57
- Issue
- 10
- Pages
- 1229-1254
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- PMC
- PMC6132501
- OpenAlex
- W2790768119
- Cited by
- 421
- References
- 288
- Citations by year
- 2026: 41 · 2025: 51 · 2024: 58 · 2023: 69 · 2022: 63 · 2021: 67 · 2020: 41 · 2019: 22 · 2018: 8
- FWCI
- 6.70
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- Locations
- Clinical Pharmacokinetics (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, other-oa)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- RePub (Erasmus University Rotterdam) (submittedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Keywords
- irinotecan, pharmacokinetics, pharmacodynamics, pharmacogenetics, SN-38, carboxylesterase, CYP3A4, UGT1A, topoisomerase I inhibitor, dose-limiting toxicity, interindividual variability, drug metabolism, genetic variants
- MeSH terms
- Irinotecan, UGT1A1 Enzyme, Drug Interactions, Humans, Inactivation, Metabolic, Tissue Distribution, Glucuronosyltransferase, Area Under Curve, Polymorphism, Single Nucleotide, Cytochrome P-450 CYP3A, Precision Medicine, Topoisomerase I Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.